Vaccines 2013, 1(3), 348-366; doi:10.3390/vaccines1030348

An HIV Vaccine for South-East Asia—Opportunities and Challenges

1 Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand 2 Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand 3 Department of Retrovirology, US Army Medical Component, Armed Forces Institute of Medical Sciences (AFRIMS), 315/6 Rajvithi Road, Bangkok 10400, Thailand 4 Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, 6720-A Rockledge Drive, Suite 400, Bethesda, MD 20817, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 3 June 2013; in revised form: 25 July 2013 / Accepted: 5 August 2013 / Published: 14 August 2013
(This article belongs to the Special Issue HIV Vaccines)
PDF Full-text Download PDF Full-Text [510 KB, uploaded 14 August 2013 11:30 CEST]
Abstract: Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.
Keywords: HIV vaccines; RV144; correlates of risk; efficacy trials; HIV-1 subtypes; Men who have sex with men; South-East Asia; Thailand; Myanmar; China

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Pitisuttithum, P.; Rerks-Ngarm, S.; O'Connell, R.J.; Kim, J.H.; Excler, J.-L. An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines 2013, 1, 348-366.

AMA Style

Pitisuttithum P, Rerks-Ngarm S, O'Connell RJ, Kim JH, Excler J-L. An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines. 2013; 1(3):348-366.

Chicago/Turabian Style

Pitisuttithum, Punnee; Rerks-Ngarm, Supachai; O'Connell, Robert J.; Kim, Jerome H.; Excler, Jean-Louis. 2013. "An HIV Vaccine for South-East Asia—Opportunities and Challenges." Vaccines 1, no. 3: 348-366.

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert